Veeva Systems is a cloud-based software company that specializes in providing solutions for the pharmaceutical and biotechnology industries. The company’s product portfolio includes solutions for customer relationship management, clinical trial management, and regulatory compliance. Veeva is publicly traded on the New York Stock Exchange under the ticker symbol VEEV.

One important metric for evaluating a company’s financial health is free cash flow (FCF), which is the amount of cash a company generates after accounting for capital expenditures. FCF is important because it shows a company’s ability to generate cash and pay dividends or make acquisitions.

Veeva Systems has a strong free cash flow position. In the most recent quarter, Veeva reported a FCF of $284.5 million, up from $221.1 million in the same quarter last year. This represents a 28.5% year-over-year growth in FCF.

This strong FCF position has allowed Veeva to make strategic acquisitions and return cash to shareholders through share buybacks and dividend payments. The company has also been able to invest in research and development and expand its product offerings.

Veeva’s financial position has been supported by its subscription-based business model, which provides a steady stream of recurring revenue. The company has also benefited from the growing demand for cloud-based solutions in the pharmaceutical and biotechnology industries.